主页 > 医药科学 >
【medical-news】绝经后行激素替代疗法的妇女LDL-
"Because studies on hormone therapy have shown that they may increase heart attacks and strokes, many women have been reluctant to use this treatment," lead author Dr. Paul F. Bray, from Jefferson Medical College in Philadelphia, said in a statement. "We found that a simple and widely used blood test may be useful to advise women if they are at an increased risk of a heart attack while undergoing hormone therapy."
In a nested case-control analysis of the WHI hormone trials, the researchers determined baseline lipid and high-sensitivity C-reactive protein (hs-CRP) levels in 271 subjects with incident coronary heart disease and in 707 women without heart disease. The women ranged from 50 to 79 years old at study entry, the researchers report in the American Journal of Cardiology for June 1st.
Women with an LDL/HDL ratio of < 2.5 had no increased risk of coronary events while using estrogen alone or with progesterone. By contrast, a ratio of 2.5 or higher was associated with a 73% increased risk (p = 0.02) of a cardiac event.
An elevated hs-CRP value was also associated with an increased risk of coronary events in women using estrogen alone, but not in those using estrogen plus progesterone, the report indicates.
While the results suggest that the LDL/HDL ratio is useful in predicting coronary risk in women starting hormone therapy, there is no evidence that it helps predict the risk of stroke, Dr. Bray emphasized.
Moreover, hormone use has been associated with a number of other conditions, such as venous thrombosis and breast cancer, for which determination of the LDL/HDL ratio is unlikely to prove useful, he added.
Am J Cardiol 2008;101:1599-1605. 认领该文48h上交 初次翻译，敬请指正
NEW YORK (Reuters Health) Jun 16 - In menopausal women who are initiating hormone replacement therapy, the LDL to HDL cholesterol ratio is a useful predictor of treatment-related coronary events, according to a report by the Women's Health Initiative investigators.
据一份女性健康初步调查（WHI）的报告表明：LDL/HDL值对于正准备用激素进行替代治疗的已停经女性来说是一个预测激素替代治疗相关冠脉事件的有用指标。
"Because studies on hormone therapy have shown that they may increase heart attacks and strokes, many women have been reluctant to use this treatment," lead author Dr. Paul F. Bray, from Jefferson Medical College in Philadelphia, said in a statement. "We found that a simple and widely used blood test may be useful to advise women if they are at an increased risk of a heart attack while undergoing hormone therapy."
费城Jefferson 医学院的Bray博士是本报告的主要作者，他在一次发言中说到：“由于有研究表明激素替代治疗可能会增加心脏病和脑卒中的发生率，许多女性已经不愿使用这种治疗方法。而我们的研究发现一个简单而广泛应用的血液检查可以用来判断这些女性在接受激素替代治疗时发生心脏病的危险是否增加，从而为她们是否采用激素替代治疗提供建议”
In a nested case-control analysis of the WHI hormone trials, the researchers determined baseline lipid and high-sensitivity C-reactive protein (hs-CRP) levels in 271 subjects with incident coronary heart disease and in 707 women without heart disease. The women ranged from 50 to 79 years old at study entry, the researchers report in the American Journal of Cardiology for June 1st.
据研究者发表在7月1日的美国心脏病杂志的报道，WHI激素实验入选了271例有冠心病事件 和707例没有心脏病的女性，入选者年龄在50到79岁不等，在进行交叉的病例对照分析后，研究者确定了脂质和高敏C反应蛋白的基线值。
Women with an LDL/HDL ratio of < 2.5 had no increased risk of coronary events while using estrogen alone or with progesterone. By contrast, a ratio of 2.5 or higher was associated with a 73% increased risk (p = 0.02) of a cardiac event.
当LDL/HDL小于2.5时单独服用雌激素或者联合服用黄体酮不会增加女性冠心病事件的发生率，相反当LDL/HDL等于或者大于2.5时服用雌激素或者联合服用黄体酮将会使女性发生心脏事件的危险升高73%（P=0.02）
An elevated hs-CRP value was also associated with an increased risk of coronary events in women using estrogen alone, but not in those using estrogen plus progesterone, the report indicates.
同样，研究结果表明单独使用雌激素的女性高敏C反应蛋白的升高与冠脉事件发生的危险增加相关，但在联合使用雌激素和黄体酮的女性人群中却无此相关性。
While the results suggest that the LDL/HDL ratio is useful in predicting coronary risk in women starting hormone therapy, there is no evidence that it helps predict the risk of stroke, Dr. Bray emphasized.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-23 17:11
医学,生命科学网